---
title: "000915.SZ (000915.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/000915.SZ/news.md"
symbol: "000915.SZ"
name: "000915.SZ"
parent: "https://longbridge.com/zh-HK/quote/000915.SZ.md"
datetime: "2026-03-12T02:11:28.137Z"
locales:
  - [en](https://longbridge.com/en/quote/000915.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000915.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000915.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/000915.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/000915.SZ/news.md)


# 000915.SZ (000915.SZ) — 相關新聞

### [Revenue Flash - Handar (6620) January revenue reached NT$75.69 million, with a year-on-year growth rate of 32.15%](https://longbridge.com/zh-HK/news/275434908.md)
*2026-02-10T09:32:16.000Z*
> Handa (6620-TW) announced that its revenue for January 2026 was NT$75.69 million, with a year-on-year growth rate of 32.

### [WIT DYNE: Currently, there is no business relationship with Nestlé](https://longbridge.com/zh-HK/news/273043056.md)
*2026-01-20T07:13:28.000Z*
> On January 20th, WIT DYNE stated on the interactive platform that the company currently has no business dealings with Ne

### [WIT DYNE's subsidiary has obtained a drug registration certificate](https://longbridge.com/zh-HK/news/271754253.md)
*2026-01-07T07:55:02.000Z*
> WIT DYNE's subsidiary Shandong Dyne Marine Biological Pharmaceutical Co., Ltd. has obtained the "Drug Registration Certi

### [WIT DYNE: The melatonin products represented by the company have not yet been launched for sale](https://longbridge.com/zh-HK/news/265860868.md)
*2025-11-14T07:16:54.000Z*
> On November 14th, WIT DYNE stated on the interactive platform that the melatonin products it represents have not yet bee

### [WIT DYNE released its performance for the first three quarters, with a net profit attributable to the parent company of 408 million yuan, a year-on-year increase of 11.67%](https://longbridge.com/zh-HK/news/262580492.md)
*2025-10-24T09:05:02.000Z*
> According to the Zhitong Finance APP, WIT DYNE released its Q3 2025 report. In the first three quarters, the company ach

### [WIT DYNE: The net profit for the third quarter was 70.5981 million yuan, a year-on-year increase of 110.42%](https://longbridge.com/zh-HK/news/262565817.md)
*2025-10-24T07:59:40.000Z*
> WIT DYNE announced that its revenue for the third quarter was 432 million yuan, a year-on-year increase of 93.28%; net p

### [WIT DYNE: A cash dividend of 5 yuan for every 10 shares](https://longbridge.com/zh-HK/news/260581768.md)
*2025-10-10T08:48:17.000Z*
> WIT DYNE announced that the interim dividend for 2025 will be based on a total share capital of 234 million shares as of

### [WIT DYNE: Actively advancing the relevant preparations for the market entry of the ManLeJing product](https://longbridge.com/zh-HK/news/255564819.md)
*2025-09-02T07:41:31.000Z*
> On September 2nd, WIT DYNE stated on the interactive platform that the company is actively advancing the relevant prepar

### [WIT DYNE has fallen for 3 consecutive days, with one fund under China Merchants Fund ranking among the top ten shareholders](https://longbridge.com/zh-HK/news/253785967.md)
*2025-08-20T10:04:47.000Z*
> WIT DYNE has fallen for three consecutive trading days, with a cumulative decline of -0.59%. The China Merchants Fund's 

### [WIT DYNE: Currently, there are no long-acting growth hormone products under research or clinical trials](https://longbridge.com/zh-HK/news/252804449.md)
*2025-08-13T07:25:56.000Z*
> On August 13th, WIT DYNE stated on the interactive platform that the company currently has no long-acting growth hormone